Cambridge, UK-based monoclonal antibody specialist Kymab Group today announced the appointment of Dr Sonia Quaratino as its first chief medical officer. Dr Quaratino will manage the clinical development of the group's expanding therapeutic antibody portfolio. 9 May 2017
US biotech Seattle Genetics has agreed to terminate its license agreement with Immunomedics for cancer drug candidate sacituzumab govitecan (IMMU-132) and settle the related litigation. 8 May 2017
Paris, France-based GenSight Biologics has appointed Mohamed Genead, the former head of ophthalmology/retina gene therapy at Biogen, as the company’s new chief medical officer. 4 May 2017
Private company ImCheck Therapeutics has raised 20 million euros ($22 million) to fund research into antibodies involved in the immune system. 3 May 2017
Dr Ellen Donnelly, former head of clinical operations of the neuroscience and pain therapeutic area at Pfizer, has been appointed as chief executive officer at Modus Therapeutics. 24 April 2017
Privately-held UK biotech firm Destiny Pharma has appointed Neil Clark as chief executive and member of the board of directors, effective immediately. 13 April 2017
David Hung, the founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer for $14 billion last year, has switched his attention to dementia in his role. 11 April 2017
USA-based Marinus Pharmaceuticals, a biotech company focused on developing treatments for epilepsy and neuropsychiatric disorders, has appointed Lorianne Masuoka as chief medical officer. 11 April 2017
Tim Harris has been appointed as executive vice president of R&D at Bioverativ, a new company focussed on hemophilia and other rare blood disorders. 11 April 2017
French pharma major Sanofi (Euronext: SAN) has promoted Bill Sibold to the post of executive vice president Sanofi Genzyme, effective July 1, 2017. In this role, Mr Sibold will be a member of the executive committee. 5 April 2017
Respiratory diseases specialist Verona Pharma has announced the appointment of Richard Hennings to the company’s senior management team as commercial director. 31 March 2017
US biotech firm Alexion Pharmaceuticals has appointed Ludwig Hantson as chief executive and member of the board of directors, effective immediately. 27 March 2017
US-based Boston Biomedical is making new senior appointments in oncology, as the company’s founder Chiang J. Li steps down from his role as chief executive. 23 March 2017
USA/Israel-based biotech firm BrainStorm Cell Therapeutics has appointed Ralph Kern to the positions of chief operating and chief medical officer, effective March 6, 2017. 6 March 2017
US biotech major Celgene Corp says that its president and chief operating officer (COO) Jacqualyn (Jackie) Fouse, has decided to retire from Celgene effective June 30, 2017. 24 February 2017
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024